1.78
price up icon0.00%   0.00
after-market 시간 외 거래: 1.75 -0.03 -1.69%
loading
전일 마감가:
$1.78
열려 있는:
$1.8
하루 거래량:
997.80K
Relative Volume:
0.51
시가총액:
$278.31M
수익:
$127.04M
순이익/손실:
$-110.56M
주가수익비율:
-1.5214
EPS:
-1.17
순현금흐름:
$-60.33M
1주 성능:
-6.81%
1개월 성능:
-16.04%
6개월 성능:
-31.80%
1년 성능:
+137.18%
1일 변동 폭
Value
$1.75
$1.85
1주일 범위
Value
$1.70
$1.885
52주 변동 폭
Value
$0.50
$3.93

Heron Therapeutics Inc Stock (HRTX) Company Profile

Name
명칭
Heron Therapeutics Inc
Name
전화
(858) 251-4400
Name
주소
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Name
직원
126
Name
트위터
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
HRTX's Discussions on Twitter

Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2020-05-27 개시 Guggenheim Buy
2020-02-20 재확인 Needham Buy
2019-01-16 재확인 Needham Buy
2018-04-05 개시 Evercore ISI Outperform
2018-03-19 재확인 Mizuho Buy
2018-03-01 재확인 Needham Buy
2018-01-03 개시 Leerink Partners Outperform
2017-09-27 개시 Northland Capital Outperform
2017-02-27 개시 Needham Buy
2016-10-26 개시 Aegis Capital Buy
2016-09-06 재개 Lake Street Buy
2016-05-03 개시 Cantor Fitzgerald Buy
2015-12-10 개시 Lake Street Buy
2015-09-23 재확인 Leerink Partners Outperform
2015-09-02 개시 BofA/Merrill Buy
2015-08-03 재확인 Brean Capital Buy
2015-06-30 재확인 JMP Securities Mkt Outperform
2015-06-19 재확인 Leerink Partners Outperform
2014-08-07 개시 Noble Financial Buy
모두보기

Heron Therapeutics Inc 주식(HRTX)의 최신 뉴스

pulisher
05:00 AM

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors - StockTitan

05:00 AM
pulisher
Oct 31, 2024

Bunion Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Heron Therapeutics, Lotus Clinical Research, Cali Pharma, Grünenthal GmbH, Pacira Pharma, Inc, Mallinckrodt - The Globe and Mail

Oct 31, 2024
pulisher
Oct 29, 2024

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 - Longview News-Journal

Oct 29, 2024
pulisher
Oct 26, 2024

SG Americas Securities LLC Cuts Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Oct 26, 2024
pulisher
Oct 21, 2024

Antinauseants Market Insights, Forecast to 2031Heron - openPR

Oct 21, 2024
pulisher
Oct 20, 2024

The Manufacturers Life Insurance Company Acquires 6,328 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Oct 20, 2024
pulisher
Oct 16, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Update - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Heron Therapeutics Inc (HRTX) deserves deeper analysis - US Post News

Oct 15, 2024
pulisher
Oct 14, 2024

Investor’s Toolkit: Key Ratios for Assessing Heron Therapeutics Inc (HRTX)’s Performance - The Dwinnex

Oct 14, 2024
pulisher
Oct 12, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Millennium Management LLC - Defense World

Oct 12, 2024
pulisher
Oct 11, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Congress Park Capital LLC - MarketBeat

Oct 11, 2024
pulisher
Oct 10, 2024

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids - The Malaysian Reserve

Oct 10, 2024
pulisher
Oct 09, 2024

Its Stock Has Paid Off Big Time For Heron Therapeutics Inc - SETE News

Oct 09, 2024
pulisher
Oct 09, 2024

AQR Capital Management LLC Raises Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat

Oct 09, 2024
pulisher
Oct 08, 2024

Heron Therapeutics Inc Inc. (HRTX) Price Performance: The Role of Supply and Demand - The InvestChronicle

Oct 08, 2024
pulisher
Oct 08, 2024

Can you now get a good deal on Heron Therapeutics Inc’s shares? - US Post News

Oct 08, 2024
pulisher
Oct 06, 2024

Squarepoint Ops LLC Purchases 286,160 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat

Oct 06, 2024
pulisher
Oct 03, 2024

Buying Buzz: Heron Therapeutics Inc [HRTX] EVP, Chief Development Officer Forbes William P purchases 25,000 shares of the company – Knox Daily - Knox Daily

Oct 03, 2024
pulisher
Oct 03, 2024

HRTX’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle

Oct 03, 2024
pulisher
Oct 03, 2024

When Can We Expect A Profit From Heron Therapeutics, Inc. (NASDAQ:HRTX)? - Simply Wall St

Oct 03, 2024
pulisher
Oct 02, 2024

Get in on Heron Therapeutics Inc’s (HRTX) buy-in window today! - SETE News

Oct 02, 2024
pulisher
Oct 02, 2024

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability - Yahoo Finance

Oct 02, 2024
pulisher
Oct 01, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Acquired by Marshall Wace LLP - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Heron Therapeutics Inc’s results are impressive - US Post News

Oct 01, 2024
pulisher
Oct 01, 2024

Marshall Wace LLP Boosts Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat

Oct 01, 2024
pulisher
Sep 30, 2024

Market Momentum Report: Heron Therapeutics Inc (HRTX)’s Negative Close at 1.99 - The Dwinnex

Sep 30, 2024
pulisher
Sep 29, 2024

Clearline Capital LP Sells 1,280,938 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat

Sep 29, 2024
pulisher
Sep 26, 2024

Heron gains on FDA nod for new Zynrelef application - MSN

Sep 26, 2024
pulisher
Sep 26, 2024

Renaissance Technologies LLC Reduces Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Sep 26, 2024
pulisher
Sep 26, 2024

Heron Therapeutics Inc [NASDAQ: HRTX] Sees Decrease in Stock Value - Knox Daily

Sep 26, 2024
pulisher
Sep 26, 2024

Renaissance Technologies LLC Lowers Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

Heron Therapeutics’ (HRTX) Buy Rating Reiterated at Needham & Company LLC - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

Needham & Company LLC Reaffirms "Buy" Rating for Heron Therapeutics (NASDAQ:HRTX) - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

Adversity is less terrifying than hope: Heron Therapeutics Inc (HRTX) - SETE News

Sep 25, 2024
pulisher
Sep 25, 2024

Heron stock gains on FDA nod for Zynrelef method (NASDAQ:HRTX) - Seeking Alpha

Sep 25, 2024
pulisher
Sep 25, 2024

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") - PR Newswire

Sep 25, 2024
pulisher
Sep 25, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Rhumbline Advisers - Defense World

Sep 25, 2024
pulisher
Sep 24, 2024

Heron Therapeutics Inc (HRTX) stock on the rise: An overview - US Post News

Sep 24, 2024
pulisher
Sep 21, 2024

Wealth Alliance Has $112,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Acadian Asset Management LLC Makes New Investment in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

E Fund Management Co. Ltd. Acquires New Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Orchard Capital Management LLC - Defense World

Sep 20, 2024
pulisher
Sep 19, 2024

Bank of New York Mellon Corp Purchases 113,655 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Pekin Hardy Strauss Inc. Has $88,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by Richmond Brothers Inc. - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Monitoring Heron Therapeutics Inc (HRTX) after recent insider movements - Knox Daily

Sep 18, 2024
pulisher
Sep 17, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Principal Financial Group Inc. - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

Heron Therapeutics Inc (HRTX) stock: A year of ups and downs - US Post News

Sep 17, 2024
pulisher
Sep 17, 2024

Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR - GlobeNewswire Inc.

Sep 17, 2024
pulisher
Sep 16, 2024

Holdings of Heron Therapeutics Inc (HRTX) are aligned with the stars - SETE News

Sep 16, 2024
pulisher
Sep 16, 2024

Market Highlights: Heron Therapeutics Inc (HRTX) Ends on a High Note at 1.87 - The Dwinnex

Sep 16, 2024

Heron Therapeutics Inc (HRTX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$19.96
price up icon 5.11%
$75.75
price down icon 0.50%
$376.80
price up icon 0.74%
$53.54
price down icon 2.00%
$207.25
price up icon 1.49%
$108.97
price down icon 2.25%
자본화:     |  볼륨(24시간):